Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Bruce Anthony Campbell CreeKrzysztof W SelmajLawrence SteinmanGiancarlo ComiAmit Bar-OrDouglas Lorne ArnoldHans-Peter HartungXavier MontalbánEva K HavrdováJames K SheffieldNeil MintonChun-Yen ChengDiego SilvaLudwig KapposJeffrey A CohenPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
This long-term extension of ozanimod trials confirmed a favorable safety/tolerability profile and sustained benefit on clinical and magnetic resonance imaging measures of disease activity.
Keyphrases
- disease activity
- multiple sclerosis
- open label
- rheumatoid arthritis
- systemic lupus erythematosus
- magnetic resonance imaging
- phase iii
- phase ii
- rheumatoid arthritis patients
- ankylosing spondylitis
- study protocol
- clinical trial
- phase ii study
- computed tomography
- white matter
- randomized controlled trial
- contrast enhanced
- squamous cell carcinoma
- double blind
- magnetic resonance
- radiation therapy